Cita APA

Motzer, R., Schmidinger, M., Figlin, R., Liu, Y., Eto, M., & Suárez, C. (2023). LITESPARK-011: Belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy.

Citación estilo Chicago

Motzer, Robert, Manuela Schmidinger, Robert Figlin, Yanfang Liu, Masatoshi Eto, y Cristina Suárez. LITESPARK-011: Belzutifan Plus Lenvatinib Vs Cabozantinib in Advanced Renal Cell Carcinoma After Anti-PD-1/PD-L1 Therapy. 2023.

Cita MLA

Motzer, Robert, et al. LITESPARK-011: Belzutifan Plus Lenvatinib Vs Cabozantinib in Advanced Renal Cell Carcinoma After Anti-PD-1/PD-L1 Therapy. 2023.